Galloflavin suppresses lactate dehydrogenase activity and causes MYC downregulation in Burkitt lymphoma cells through NAD/NADH-dependent inhibition of sirtuin-1

Anti-Cancer Drugs

Volumn 24, Issue 8, 2013, Pages 862-870

  Vettraino, Marina ^a   Manerba, Marcella ^a   Govoni, Marzia ^a   Di Stefano, Giuseppina ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Burkitt lymphoma; cancer cell metabolism; lactate dehydrogenase; MYC protein

Indexed keywords

ADENOSINE TRIPHOSPHATE; ANTINEOPLASTIC AGENT; GALLOFLAVIN; LACTATE DEHYDROGENASE; LACTIC ACID; MYC PROTEIN; NICOTINAMIDE ADENINE DINUCLEOTIDE; OXAMIC ACID; OXIDOREDUCTASE INHIBITOR; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE; SIRTUIN 1; UNCLASSIFIED DRUG;

ARTICLE; BURKITT LYMPHOMA; CANCER CELL; CANCER INHIBITION; CELL DIVISION; CELL RESPIRATION; CHROMOSOME TRANSLOCATION; DOWN REGULATION; ENZYME ACTIVITY; ENZYME REPRESSION; ENZYME SUBUNIT; EPSTEIN BARR VIRUS; HUMAN; HUMAN CELL; LYMPHOBLAST; LYMPHOBLASTOID CELL; MITOCHONDRIAL RESPIRATION; ONCOGENE MYC; PRIORITY JOURNAL; PROTEIN EXPRESSION; SURVIVAL; UPREGULATION;

ADENOSINE TRIPHOSPHATE; BURKITT LYMPHOMA; CELL LINE, TUMOR; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; ENZYME INHIBITORS; HISTONE DEACETYLASE INHIBITORS; HUMANS; INHIBITORY CONCENTRATION 50; ISOCOUMARINS; ISOENZYMES; L-LACTATE DEHYDROGENASE; LACTIC ACID; NAD; PROTO-ONCOGENE PROTEINS C-MYC; SIGNAL TRANSDUCTION; SIRTUIN 1; TIME FACTORS;

EID: 84881075072     PISSN: 09594973     EISSN: 14735741     Source Type: Journal    
DOI: 10.1097/CAD.0b013e328363ae50     Document Type: Article

References (37)

1. Pelicano H, Martin DS, Xu RH, Huang P. Glycolysis inhibition for anticancer treatment. Oncogene 2006; 25:4633-4646.
2. Levine AJ, Puzio-Kuter AM. The control of the metabolic switch in cancers by oncogenes and tumor suppressor genes. Science 2010; 330: 1340-1344.
3. Gatenby RA, Gillies RJ. Why do cancer have high aerobic glycolysis? Nat Rev Cancer 2004; 4:891-899.
4. Dang CV, Le A, Gao P. MYC-induced cancer cell energy metabolism and therapeutic opportunities. Clin Cancer Res 2009; 15:6479-6483.
5. Kim JW, Dang CV. Cancer's molecular sweet tooth and the Warburg effect. Cancer Res 2006; 66:8927-8930.
6. Shim H, Dolde C, Lewis BC, Wu CS, Dang G, Jungmann RA, et al. c-Myc transactivation of LDH-A: implications for tumor metabolism and growth. Proc Natl Acad Sci USA 1997; 94:6658-6663.
7. Everse J, Kaplan NO. Lactated dehydrogenases: structure and function. Adv Enzymol 1973; 37:61-133.
8. Granchi C, Bertini S, Macchia M, Minutolo F. Inhibitors of lactate dehydrogenase isoforms and their therapeutic potentials. Curr Med Chem 2010; 17:672-697.
9. Zha X, Wang F, Wang Y, He S, Jing Y, Wu X, et al. Lactate dehydrogenase B is critical for hyperactive mTOR-mediated tumorigenesis. Cancer Res 2011; 71:13-18.
10. Kinoshita T, Nohata N, Yoshino H, Hanazawa T, Kikkawa N, Fujimura L, et al. Tumor suppressive microRNA-375 regulates lactate dehydrogenase B in maxillary sinus squamous cell carcinoma. Int J Oncol 2012; 40:185-193.
11. Fiume L. Inhibition of aerobic glycolysis in Yoshida ascites hepatoma by tartronic acid. Nature 1960; 187:792-793.
12. Papacostantinou J, Colowick SP. The role of glycolysis in the growth of tumor cells. I. Effects of oxamic acid on the metabolism of Ehrlich tumor cells in vitro. J Biol Chem 1961; 236:278-284.
13. Fantin VR, St-Pierre J, Leder P. Attenuation of LDH-A expression uncovers a link between glycolysis, mitochondrial physiology and tumor maintenance. Cancer Cell 2006; 9:425-434.
14. Le A, Cooper CR, Gouw AM, Dinavahi R, Maitra A, Deck LM, et al. Inhibition of lactate dehydrogenase A induces oxidative stress and inhibits tumor progression. Proc Natl Acad Sci USA 2010; 107:2037-2042.
15. Manerba M, Vettraino M, Fiume L, Di Stefano G, Sartini A, Giacomini E, et al. Galloflavin (CAS 568-80-9): a novel inhibitor of lactate dehydrogenase. ChemMedChem 2012; 7:311-317.
16. Farabegoli F, Vettraino M, Manerba M, Fiume L, Di Stefano G. Galloflavin, a new lactate dehydrogenase inhibitor, induces the death of human breast cancer cells with different glycolytic attitude by affecting distinct signaling pathways. Eur J Pharm Sci 2012; 47:729-738.
17. Slack GW, Gascoyne RD. MYC and aggressive B-cell lymphomas. Adv Anat Pathol 2011; 18:219-228.
18. Just T, Burgwald H, Broe MK. Flow cytometric detection of EBV (EBER snRNA) using peptide nucleic acid probes. J Virol Methods 1998; 73: 163-174.
19. Marchini A, Longnecker R, Kieff E. Epstein-Barr virus (EBV)-negative B-lymphoma cell lines for clonal isolation and replication of EBV recombinants. J Virol 1992; 66:4972-4981.
20. Novoa WB, Winer AD, Glaid AJ, Schwert GW. Lactic dehydrogenase. V. Inhibition by oxamate and by oxalate. J Biol Chem 1959; 234:1143-1148.
21. Goldman RD, Kaplan NO, Hall TC. Lactic dehydrogenase in human neoplastic tissues. Cancer Res 1964; 24:389-399.
22. Barker SB, Summerson WH. The colorimetric determination of lactic acid in biological material. J Biol Chem 1941; 138:535-554.
23. Umemura K, Kimura H. Determination of oxidized and reduced nicotinamide adenine dinucleotide in cell monolayer using a single extraction procedure and a spectrophotometric assay. Anal Biochem 2005; 338:131-135.
24. Houtkooper RH, Cantò C, Wanders RJ, Auwerx J. The secret life of NAD +: an old metabolite controlling new metabolic signaling pathways. Endocr Rev 2010; 31:194-223.
25. Lin SJ, Guarente L. Nicotinamide adenine dinucleotide, a metabolic regulator of transcription, longevity and disease. Curr Opin Cell Biol 2003; 15:241-246.
26. Mao B, Zaho G, Lv X, Chen HZ, Xue Z, Yang B, et al. Sirt1 deacetylates c-Myc and promotes c-Myc/Max association. Int J Biochem Cell Biol 2011; 43:1573-1581.
27. Li K, Luo J. The role of SIRT1 in tumorigenesis. N Am J Med Sci 2011; 4:104-106.
28. Sachaf GM, Gentles AJ, Elchuri S, Sahoo D, Soen Y, Sharpe O, et al. Genomic and proteomic analysis reveals a threshold level of MYC required for tumor maintenance. Cancer Res 2008; 68:5132-5142.
29. Bellance N, Lestienne P, Rossignol R. Mitochondria: from bioenergetics to the metabolic regulation of carcinogenesis. Front Biosci 2009; 14: 4015-4034.
30. Milner J. Cellular regulation of SIRT1. Curr Pharm Des 2009; 15:39-44.
31. Rodgers JT, Lerin C, Haas W, Gygi SP, Spiegelman BM, Puigserver P. Nutrient control of glucose homeostasis through a complex of PGC-1a and SIRT1. Nature 2005; 434:113-118.
32. Jang KY, Hwang SH, Kwon KS, Kim KR, Choi HN, Lee NR, et al. SIRT1 expression is associated with poor prognosis of diffuse large B-cell lymphoma. Am J Surg Pathol 2008; 32:1523-1531.
33. Menssen A, Hydbring P, Kapelle K, Vervoorts J, Diebold J, Lüscher B, et al. The c-MYC oncoprotein, the NAMPT enzyme, the SIRT1-inhibitor DBC1, and the SIRT1 deacetylase form a positive feedback loop. Proc Natl Acad Sci USA 2012; 109:E187-E196.
34. Hermeking H. The MYC oncogene as a cancer drug target. Curr Cancer Drug Targets 2003; 3:163-175.
35. Soucek L, Whitfield J, Martins CP, Finch AJ, Murphy DJ, Sodir NM, et al. Modeling Myc inhibition as a cancer therapy. Nature 2008; 455:679-683.
36. Knight JRP, Milner J. SIRT1, metabolism and cancer. Curr Opin Oncol 2012; 24:68-75.
37. Ford J, Jiang M, Milner J. Cancer-specific functions of SIRT1 enable human epithelial cancer cell growth and survival. Cancer Res 2005; 65:10457-10463.